Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Observational and epidemiological studies suggest that menopausal hormone therapy (MHT) reduces cardiovascular disease (CVD) risk. However, results from prospective trials showed neutral or adverse effects most likely due to differences in participant demographics, such as age, timing of initiation of treatment, and preexisting cardiovascular disease, which reflected in part the lack of basic science information on mechanisms of action of hormones on the vasculature at the time clinical trials were designed. The Kronos Early Estrogen Replacement Study (KEEPS) is a prospective, randomized, controlled trial designed, using findings from basic science studies, to test the hypothesis that MHT when initiated early in menopause reduces progression of atherosclerosis. KEEPS participants are younger, healthier, and within 3 years of menopause thus matching more closely demographics of women in prior observational and epidemiological studies than women in the Women's Health Initiative hormone trials. KEEPS will provide information relevant to the critical timing hypothesis for MHT use in reducing risk for CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989 · cited 1×
“These observations are in agreement with other studies and support the emerging concept that CAC may be a common endpoint of multiple etiologies and may be a sensitive indicator of atherosclerosis in middle-aged humans [20, 21, 26, 54, 94].”
ResultValery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065 · cited 2×
“This age and timing of MHT initiation contrasts with that of participants in the WHI who were an average of 63 years of age at MHT initiation, approximately 12 years past menopause [46, 59].”
MethodResultSelf-citationThe use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 1×
“Furthermore, MHT was reported in both observational studies and randomized clinical trials to significantly reduce the risk of osteoporosis-related fractures [12, 23, 65] and colon cancer [27] while increasing age-adjusted incidence of breast cancer by about 20% [6, 17, 76], but decreasing breast cancer mortality by o…”
BackgroundEffects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Grodstein, F., Manson, J. E., Colditz, G. A., Willett, W. C., Speizer, F. E., & Stampfer, M. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-12-200012190-00008 · Cited by 1,063 · cited 1×
“Human Studies Over the past 30 years, numerous large observational studies [9, 10, 24, 32, 34, 37, 84, 97] found that MHT, in addition to reducing menopausal symptoms, reduced both CVD incidence and all-cause mortality by nearly one half in postmenopausal women.”
BackgroundSelf-citationRocca, W. A., Bower, J. H., Maraganore, D. M., Ahlskog, J. E., Grossardt, B. R., de Andrade, M., & Melton, L. J. (2007) · Neurology · doi:10.1212/01.wnl.0000276984.19542.e6 · Cited by 827
Estrogen Therapy and Coronary-Artery Calcification
Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071513 · Cited by 711
Self-citationOckene, I. S., & Miller, N. H. (1997) · Circulation · doi:10.1161/01.cir.96.9.3243 · Cited by 541
Patient-specific decisions about hormone replacement therapy in postmenopausal women
Col, N. F. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540380054031 · Cited by 229 · cited 1×
“Based on the expectation of CVD protection, the benefit/risk ratio for MHT was calculated to be positive for most women [16].”
BackgroundPredicting cardiovascular events with coronary calcium scoring
Weintraub, W. S., & Diamond, G. A. (2008) · New England Journal of Medicine · doi:10.1056/nejme0800676 · Cited by 40 · cited 1×
“These observations are in agreement with other studies and support the emerging concept that CAC may be a common endpoint of multiple etiologies and may be a sensitive indicator of atherosclerosis in middle-aged humans [20, 21, 26, 54, 94].”
ResultOophorectomy as a risk factor for coronary heart disease
Jacoby, V. L., Grady, D., & Sawaya, G. F. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.08.045 · Cited by 31 · cited 1×
“Furthermore, data are emerging from observational studies of women postovariectomy suggesting that MHT reduces overall mortality and maintains cardiovascular health and neurological function [3, 25, 29, 48, 51, 57, 67–70].”
Background
Cited by
Gleason, C. E., Dowling, N. M., Wharton, W., Manson, J. E., Miller, V. M., Atwood, C. S., Brinton, E. A., Cedars, M. I., Lobo, R. A., Merriam, G. R., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001833 · Cited by 490
Self-citationManagement of Menopausal Symptoms: A Review
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023) · JAMA · doi:10.1001/jama.2022.24140 · Cited by 316
Self-citationEstrogen, hormonal replacement therapy and cardiovascular disease
Yang, X.-P., & Reckelhoff, J. F. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283431921 · Cited by 272
Juster, R.-P., Bizik, G., Picard, M., Arsenault-Lapierre, G., Sindi, S., Trepanier, L., Marin, M.-F., Wan, N., Sekerovic, Z., Lord, C., et al. (2011) · Development and Psychopathology · doi:10.1017/s0954579411000289 · Cited by 268
“…before damages linked to estrogen deficiency were present and potentially irreversible, therefore rendering HT more harmful than beneficial in later life (Harman, Brinton, et al., 2005; Harman, Naftolin, Brinton, & Judelson, 2005; Low et al., 2002; Miller et al., 2009; Rossouw et al., 2007).”
BackgroundSex-Specific Physiology and Cardiovascular Disease
Shufelt, C. L., Pacheco, C., Tweet, M. S., & Miller, V. M. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-77932-4_27 · Cited by 168
Self-citation
Metadata
- Authors
- Miller, V. M., Black, D. M., Brinton, E. A., Budoff, M. J., Cedars, M. I., Hodis, H. N., Lobo, R. A., Manson, J. E., Merriam, G. R., Naftolin, F., Santoro, N., Taylor, H. S., & Harman, S. M.
- Venue
- Journal of Cardiovascular Translational Research
- Published
- 2009-05-22
- Volume
- 2
- Issue
- 3
- Pages
- 228-239
- ISSN
- 1937-5387 (ISSN-L)
- 1937-5395
- OpenAlex
- W2137482825
- Cited by
- 136
- References
- 14
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.